Home / Countries / Belgium

WHO European Region · country profile

HIV, PrEP and sexual health access in Belgium

Belgium: 91% of verified HIV medicine records are reimbursed; PrEP is available and reimbursed; sexuality education is classified as progressive. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 02/11/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

Read more: HIV medicines in BelgiumPrEP in BelgiumDoxyPEP in BelgiumSexuality education in BelgiumAbortion and contraception rules in BelgiumHealthcare for migrants in Belgium

HIV medicines91% reimbursed29 of 32 verified recordsPrEPReimbursed8,727 PrEP recipients (2024; UNAIDS GAM)DoxyPEPAvailable, not reimbursedNational access and guidanceSexuality educationProgressivePolicy frameworkFamily planning & abortionProgressiveAbortion law and contraceptionMigrant healthcare accessSuccessEntitlement and practice

10 HIV medicine records for Belgium are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in Belgium?

Of 32 verified HIV medicine records for Belgium, 29 are available and reimbursed (91%), 1 are available but not reimbursed and 2 are not available. 10 further records are still under review.

Reimbursed 29

Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Epivir, Eviplera, Generic TDF/FTC (Emtricitabine/Tenofovir DF), Genvoya, Intelence, Isentress, Juluca, Kaletra and 15 more

Available, not reimbursed 1

Rukobia

Not available 2

Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz)

See every medicine with its source ↓

Is PrEP available and reimbursed in Belgium?

Yes. In SHAPE's review, PrEP is available and reimbursed in Belgium.

PrEP recipients: 8,727 PrEP recipients (2024; UNAIDS GAM)

UNAIDS GAM 2025 reports 8,727 people receiving PrEP in 2024. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in Belgium?

DoxyPEP can be accessed in Belgium, but SHAPE's review did not find it reimbursed.

BREACH does not endorse widespread DoxyPEP use in Belgium because of antimicrobial-resistance and microbiome concerns. Individual prescribing may occur under medical supervision, preferably in a research context; a national reimbursement programme was not confirmed. [Source: https://breach-hiv.be/wp-content/uploads/2024/03/DoxyPEP-Breach-statement-AL.pdf]

What is the policy on sexuality education in Belgium?

SHAPE classifies the sexuality education framework in Belgium as progressive. This describes the national policy framework, not how every school delivers it.

  • National framework: Relationships and sexual health are included in compulsory learning objectives, but curricula and delivery differ across the Flemish, French and German-speaking communities.
  • Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in Belgium?

SHAPE classifies family planning and abortion rights in Belgium as progressive, combining abortion law and contraception policy.

  • Abortion: Abortion is available on request through 12 weeks after conception; mandatory consultation and a waiting period apply.
  • Contraception: EPF's 2026 contraception-policy score is 89.8%; the atlas records partial national coverage.
  • Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/countries/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf]

Can migrants access healthcare in Belgium?

SHAPE's editorial comparison places migrant healthcare access in Belgium in the most accessible category (Success). Entitlement: CPAS Urgent Medical Aid route for people without lawful residence.

Provider type: Public/social insurance system / CPAS / NGO · International migrants (2024): 2,349,032

  • Access rule: Undocumented people may request Urgent Medical Aid through the municipal CPAS; despite its name, approved assistance can cover preventive, curative and chronic care.
  • Main barriers: A means inquiry, proof of residence and local administrative practice can delay or deter access.
  • Migration measure: UN DESA estimates 2,349,032 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
  • Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
  • Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
  • Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Morocco (10.5%), France (8.4%), Netherlands (5.8%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 75.4%; Late HIV Diagnosis (CD4 <350, 2024): 35.3%

How Belgium compares

Belgium ranks #6 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (91%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

All HIV medicines in Belgium

MedicineActive ingredientClassStatusEvidence and sourceChecked
Biktarvy
Gilead Sciences
Bictegravir / Emtricitabine / TAFINSTI + NRTI/NtRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Celsentri
ViiV Healthcare
MaravirocEntry InhibitorReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Delstrigo
Merck
Doravirine / Lamivudine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Descovy
Gilead Sciences
Emtricitabine / TAFNRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Dovato
ViiV Healthcare
Dolutegravir / LamivudineINSTI + NRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Edurant
Janssen
RilpivirineNNRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Epivir
ViiV Healthcare
LamivudineNRTIReimbursedListed on the official national reimbursement list (RIZIV reference file 01/11/2026). Details: S_COD 00239264/00239365/00401942: Chapter IV A-20; reimbursement base 66.30 EUR (CNK list price, from 2026-01-01). Source: https://www.riziv.fgov.be/SiteCollectionDocuments/liste_specialites_20261101.xlsx. Verified 2026-11-02.02/11/2026
Eviplera
Gilead Sciences
Rilpivirine / Emtricitabine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursedListed on the official national reimbursement list (RIZIV reference file 01/11/2026). Details: S_COD 01051236/01541947: Chapter IV A-20; reimbursement base 533.10 EUR from 2026-01-01. Source: https://www.riziv.fgov.be/SiteCollectionDocuments/liste_specialites_20261101.xlsx. Verified 2026-11-02.02/11/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF)
Multiple (Generics)
Emtricitabine / Tenofovir DFNRTIReimbursedGeneric combinations are widely accessible and reimbursed under standard national health policies. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Genvoya
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / TAFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Intelence
Janssen
EtravirineNNRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Isentress
Merck
RaltegravirINSTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Juluca
ViiV Healthcare
Dolutegravir / RilpivirineINSTI + NNRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Kaletra
AbbVie
Lopinavir / RitonavirPIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Kivexa
ViiV Healthcare
Abacavir / LamivudineNRTIReimbursedListed on the official national reimbursement list (RIZIV reference file 01/11/2026). Details: S_COD 00555627/01459873: Chapter IV A-20; reimbursement base 152.32 EUR from 2026-01-01. Source: https://www.riziv.fgov.be/SiteCollectionDocuments/liste_specialites_20261101.xlsx. Verified 2026-11-02.02/11/2026
Odefsey
Gilead Sciences
Rilpivirine / Emtricitabine / TAFNNRTI + NRTI/NtRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Pifeltro
Merck
DoravirineNNRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Prezista
Janssen
DarunavirPIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Rekambys
Janssen
RilpivirineLong-Acting NNRTIReimbursedLong-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Belgium record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Rezolsta
Janssen
Darunavir / CobicistatPI + pharmacokinetic enhancerReimbursedListed on the official national reimbursement list (RIZIV reference file 01/11/2026). Details: S_COD 01300810: Chapter IV A-20; reimbursement base 403.52 EUR from 2026-01-01. Source: https://www.riziv.fgov.be/SiteCollectionDocuments/liste_specialites_20261101.xlsx. Verified 2026-11-02.02/11/2026
Stribild
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedListed on the official national reimbursement list (RIZIV reference file 01/11/2026). Details: S_COD 01149044: Chapter IV A-20; reimbursement base 766.46 EUR from 2026-01-01. Source: https://www.riziv.fgov.be/SiteCollectionDocuments/liste_specialites_20261101.xlsx. Verified 2026-11-02.02/11/2026
Sunlenca
Gilead Sciences
LenacapavirCapsid InhibitorReimbursedApproved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Symtuza
Janssen
Darunavir / Cobicistat / Emtricitabine / TAFPI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.ema.europa.eu/en/medicines/human/variation/symtuza]14/09/2026
Tivicay
ViiV Healthcare
DolutegravirINSTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Triumeq
ViiV Healthcare
Dolutegravir / Abacavir / LamivudineINSTI + NRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Truvada
Gilead Sciences
Emtricitabine / Tenofovir DFNRTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Viread
Gilead Sciences
Tenofovir DFNtRTIReimbursedListed on the official national reimbursement list (RIZIV reference file 01/11/2026). Details: S_COD 00432052: Chapter IV A-73; reimbursement base 135.63 EUR from 2026-01-01. Source: https://www.riziv.fgov.be/SiteCollectionDocuments/liste_specialites_20261101.xlsx. Verified 2026-11-02.02/11/2026
Vocabria
ViiV Healthcare
CabotegravirINSTIReimbursedFully financed through the national health insurance framework via specialized clinic infrastructure. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Vocabria / Rekambys
ViiV Healthcare / Janssen
Cabotegravir / RilpivirineLong-Acting ARTReimbursedEMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: Local Ministry of Health / ECDC reports; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Rukobia
ViiV Healthcare
FostemsavirAttachment InhibitorAvailable, not reimbursedApproved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir)
Multiple (Generics)
Tenofovir DF / Lamivudine / DolutegravirINSTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz)
Multiple (Generics)
Tenofovir DF / Lamivudine / EfavirenzNNRTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports]14/09/2026
Apretude
ViiV Healthcare
Cabotegravir (PrEP)INSTI (Long-Acting PrEP)Under reviewLong-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis in adults and adolescents from 12 years weighing at least 35 kg. EMA confirms an EU/EEA-wide marketing authorisation granted by the European Commission on 19 September 2023. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude]14/09/2026
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris
Viatris Limited
Emtricitabine / Rilpivirine / Tenofovir alafenamideNNRTI + NRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 19 August 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris]14/09/2026
Emtricitabine / Tenofovir alafenamide Viatris
Viatris Limited
Emtricitabine / Tenofovir alafenamideNRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 18 July 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-alafenamide-viatris]14/09/2026
Emtriva
Gilead Sciences
EmtricitabineNRTIUnder reviewEmtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva]14/09/2026
Evotaz
Bristol Myers Squibb
Atazanavir / CobicistatPI + pharmacokinetic enhancerUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 13 July 2015. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz]14/09/2026
Norvir
AbbVie
RitonavirPI + pharmacokinetic enhancerUnder reviewRitonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. EU regulatory update (as of 5 Oct 2026): on 18 September 2025 the CHMP adopted a positive opinion recommending changes to the existing indication and contraindications of Norvir, including guidance that when ritonavir is used as a pharmacokinetic enhancer the SmPC of the co-administered protease inhibitor should be consulted for contraindications. European Commission decision not confirmed during this review. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir; https://www.ema.europa.eu/en/medicines/human/variation/norvir]14/09/2026
Retrovir
ViiV Healthcare
ZidovudineNRTIUnder reviewZidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir]14/09/2026
Reyataz
Bristol Myers Squibb
AtazanavirPIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 2 March 2004. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz]14/09/2026
Yeytuo
Gilead Sciences
Lenacapavir (PrEP)Capsid Inhibitor (Long-Acting PrEP)Under reviewTwice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]14/09/2026
Ziagen
ViiV Healthcare
AbacavirNRTIUnder reviewAbacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen]14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

  • aidsinfo.unaids.org https://aidsinfo.unaids.org/dataset
  • breach-hiv.be https://breach-hiv.be/wp-content/uploads/2024/03/DoxyPEP-Breach-stat…
  • unesco.org https://www.unesco.org/gem-report/en/peer
  • who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
  • bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
  • abortion-policies.srhr.org https://abortion-policies.srhr.org/countries/
  • epfweb.org https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_20…
  • who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
  • ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
  • home-affairs.ec.europa.eu https://home-affairs.ec.europa.eu/policies/migration-and-asylum/asyl…
  • health.ec.europa.eu https://health.ec.europa.eu/social-determinants/migrants-health_en
  • belgium.be https://www.belgium.be/fr/famille/aide_sociale/cpas
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/apretude
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilp…
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-teno…
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva
  • riziv.fgov.be https://www.riziv.fgov.be/SiteCollectionDocuments/liste_specialites_…
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/norvir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/norvir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
  • pharmiweb.com https://www.pharmiweb.com/press-release/2025-01-31/european-commissi…
  • i-base.info https://i-base.info/htb/50121
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/symtuza
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen

Explore more

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.